Patent intelligence · US
US 7338652
Methods for positron emission imaging with radiolabeled halogenated xanthenes diagnostic agents
Methods for positron emission imaging with radiolabeled halogenated xanthenes diagnostic agents
Patent details — US 7338652
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 4, 2008
- Expiration
- Feb 28, 2028
- Applicant
- Provectus Pharmatech, Inc.
- Claims
- 4
- CPC classes
- A61K, A61K51/0421
Quick answer
US 7338652 (Methods for positron emission imaging with radiolabeled halogenated xanthenes diagnostic agents) is held by Provectus Pharmatech, Inc.. Status: granted. Granted Mar 4, 2008. Expires Feb 28, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Provectus Pharmatech, Inc.
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K51/0421
More from Provectus Pharmatech, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12377068
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 12133840
Halogenated xanthene composition and method for treating hematologic cancers
granted -
US 12064507
Composition and method for oral treatment of leukemia
granted -
US 11974980
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 11975106
Uses of halogenated xanthenes in oncology and virology
granted -
US 11938182
Halogenated xanthenes as vaccine adjuvants
granted -
US 11426379
Combination of local and systemic therapies for enhanced treatment of dermatologic conditions
granted -
US 11419844
Halogenated xanthene composition and method for treating hematologic cancers
granted
Frequently asked questions
What is US patent 7338652?
US 7338652 (Methods for positron emission imaging with radiolabeled halogenated xanthenes diagnostic agents) is held by Provectus Pharmatech, Inc.. Status: granted. Granted Mar 4, 2008. Expires Feb 28, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7338652?
Provectus Pharmatech, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 29 pharmaceutical patents for this assignee.
When does US 7338652 expire?
Our index shows an expiration date of Feb 28, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.